Lopinavir/ritonavir dosage form affects quality of life during monotherapy in HIV-positive adults.

about

Ritonavir-boosted protease inhibitors in HIV therapy.

P2860

Q37866319-52146603-2CB2-49D7-B2FD-87A884564E9D

P2860

Lopinavir/ritonavir dosage form affects quality of life during monotherapy in HIV-positive adults.

Item

http://www.wikidata.org/entity/Q42907386

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Lopinavir/ritonavir dosage for ...... herapy in HIV-positive adults.

@en

Lopinavir/ritonavir dosage for ...... herapy in HIV-positive adults.

@nl

type

Item

label

Lopinavir/ritonavir dosage for ...... herapy in HIV-positive adults.

@en

Lopinavir/ritonavir dosage for ...... herapy in HIV-positive adults.

@nl

prefLabel

Lopinavir/ritonavir dosage for ...... herapy in HIV-positive adults.

@en

Lopinavir/ritonavir dosage for ...... herapy in HIV-positive adults.

@nl

P1476

Lopinavir/ritonavir dosage for ...... herapy in HIV-positive adults.

@en

P2093

Bernie Miguel

http://www.w3.org/2001/XMLSchema#string

Bryan A Lipman

http://www.w3.org/2001/XMLSchema#string

Carl Mayberry

http://www.w3.org/2001/XMLSchema#string

John J Nemecek

http://www.w3.org/2001/XMLSchema#string

Joseph C Gathe

http://www.w3.org/2001/XMLSchema#string

Rosa F Yeh

http://www.w3.org/2001/XMLSchema#string

P2860

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

Prevalence and impact of diarrhea on health-related quality of life in HIV-infected patients in the era of highly active antiretroviral therapy.

Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules

Class-sparing regimens for initial treatment of HIV-1 infection.

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions.

Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV).

Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients.

A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis S

HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.

Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients.

P304

273-277

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1545109710374997

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20841439

http://www.w3.org/2001/XMLSchema#string

P921

quality of life

Lopinavir/ritonavir dosage form affects quality of life during monotherapy in HIV-positive adults.

about

P2860

P2860

Lopinavir/ritonavir dosage form affects quality of life during monotherapy in HIV-positive adults.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921